论文部分内容阅读
目的 Chemotherapy can increase treatment-related mortality associated with future hematopoietic stem cell transplantation (HSCT) for patients with relapsed/refractory acute myeloid leukemia (AML) There is usually insufficient time to find a suitable unrelated donor for these patients.We report on the use of decitabine, a DNA methyltransferase inhibitor as a conditioning regimen for a patient undergoing HSCT.